The Adult ADHD Surge: What Private Practice Therapists Need to Know in 2026

The scale of adult ADHD in the United States is larger than most therapists realize, and it arrived faster than the treatment infrastructure to support it.

A Centers for Disease Control and Prevention survey conducted in October and November 2023 — the most comprehensive federal measurement of adult ADHD diagnosis rates to date — found that 6.0 percent of U.S. adults, approximately 15.5 million people, carry a current ADHD diagnosis (CDC/NCHS Rapid Surveys System, 2023). Among adults aged 18 to 24, that number is 21.7 percent: nearly one in four young adults has been diagnosed.

Two findings from that survey carry direct implications for private practice. First, 55.9 percent of diagnosed adults received their diagnosis in adulthood — not as children. These are not people returning to childhood therapists for continuity of care. They are adults who entered the mental health system recently, often in their 20s, 30s, and 40s, seeking help for a condition they had been living with unrecognized for decades.

Second, 36.5 percent of adults with a current ADHD diagnosis reported receiving no treatment of any kind in the past 12 months — no medication, no therapy, no coaching (CDC/NCHS Rapid Surveys System, 2023). That is more than five million adults with a confirmed diagnosis and no care. The supply problem is not primarily diagnosis. It is access to ongoing treatment.

October is ADHD Awareness Month, and this year's awareness calendar lands against an industry that has just gone through a significant disruption. Understanding what changed — and why it creates a specific opening for private practice therapists — is the focus of this post.

The public conversation about ADHD was shaped for decades by the image of a hyperactive child who couldn't sit still in elementary school. That image crowded out a more accurate one.

Attention-deficit/hyperactivity disorder did not appear in diagnostic criteria for adults until the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders in 1994, and even then the threshold was narrow: onset had to be documented before age seven. The DSM-5, published in 2013, raised the age-of-onset criterion to twelve and explicitly acknowledged that symptoms can persist into adulthood or first become impairing in adult contexts — a change that opened diagnostic pathways to a much larger population.

What followed was a slow realization, accelerating sharply after 2020, that a substantial portion of the adult population had been navigating ADHD-driven challenges without a framework. Women in particular had been systematically underdiagnosed: presentations without hyperactivity, higher rates of internalized symptoms, and social expectations that masked impairment meant that girls and women frequently received anxiety or depression diagnoses instead of ADHD evaluations.

The pandemic accelerated adult diagnosis in three concrete ways. First, telehealth removed geographic and financial barriers to assessment. Second, remote work stripped away the external scaffolding — commute routines, office schedules, shared physical space — that had helped many undiagnosed people compensate. Third, for many adults, the enforced slowdown of 2020 was the first time they could clearly observe their own behavioral patterns. What emerged was a massive wave of adults seeking evaluation, many of whom received their first ADHD diagnosis in their 30s, 40s, or 50s.

The diagnosis wave created a market, and two companies moved aggressively to capture it.

Cerebral and Done Health (later Done Global) both launched in the early 2020s with a similar model: direct-to-consumer digital platforms offering fast access to ADHD evaluation and, within appointments, stimulant medication prescriptions. Their marketing reached millions of adults who had been waiting months for a psychiatry appointment. Their promise was convenience; their business model depended on volume.

Federal investigators alleged that both companies had crossed from convenient access into aggressive prescription practices that prioritized growth over clinical standards. The outcomes were stark.

Cerebral entered into a non-prosecution agreement with the U.S. Department of Justice in November 2024, agreeing to forfeit $3.6 million for engaging in business practices that encouraged the unauthorized distribution of controlled substances. DOJ prosecutors documented that Cerebral's internal metrics and compensation structures created pressure on prescribers to issue stimulant prescriptions even when not clinically warranted (Department of Justice, 2024).

Done Health's consequences were more severe. The company's CEO, Ruthia He, and its clinical president, David Brody, were convicted on federal charges in November 2025 — the first-ever federal drug distribution prosecution related to telehealth. In July 2026, the U.S. Department of Justice announced their sentences: Ruthia He received 72 months (six years) in federal prison and a $1 million fine; Brody received 24 months and a $1 million fine. The charges encompassed a $90 million scheme to distribute more than 37 million Adderall pills over the internet and over $12 million in health care fraud (Department of Justice, 2026).

The DEA's press release described the case as involving millions spent on social media advertising designed to convince people they had ADHD, mass false diagnoses, and distribution of stimulants to patients flagged internally as showing signs of Adderall psychosis, bipolar disorder, or worsening depression — conditions that contraindicate stimulant prescriptions.

Before the pandemic, prescribing Schedule II controlled substances via telehealth required a prior in-person evaluation. Emergency COVID-19 rules suspended that requirement. When the public health emergency ended, the DEA moved to reimpose the in-person requirement — but the complexity of the transition, including the absence of enough in-person prescribers to absorb the new patient volume, forced a series of extensions.

On January 2, 2026, the DEA and HHS announced a fourth extension, keeping the existing telehealth controlled-substance prescribing flexibilities in place through December 31, 2026. The regulatory outcome after that date — whether an in-person requirement is finally reimposed or another extension is granted — will shape prescribing infrastructure for years and will directly determine how accessible stimulant prescriptions remain without an in-person evaluation.

The criminal convictions and DOJ settlements did something beyond shutting down specific companies: they permanently altered client expectations about where to get ADHD care.

Adults who had received diagnoses through Done, Cerebral, and similar platforms found themselves without a stable care provider. Many had ongoing prescriptions through primary care physicians willing to manage their medication, but had never received the behavioral and psychological components of ADHD treatment — the components that medication does not address.

Behavioral Health Business reported in July 2026 that virtual ADHD providers that survived the enforcement wave were actively pivoting toward coaching and therapy, precisely because psychological treatment had always been the defensible clinical service. The implication for private practice therapists is direct: a large, newly-diagnosed population is actively looking for ADHD-focused psychological care, and the companies that previously absorbed their attention have either exited the field or repositioned around services that therapists already provide.

These clients also tend to be private pay. Adults who spent $150 to $300 per month on Done or Cerebral were accustomed to paying directly for mental health services. Many are skeptical of insurance-managed care after their telehealth experience. They're a natural fit for the out-of-pocket private practice model — a point worth noting for therapists weighing the insurance versus private-pay decision.

Return to the CDC finding: 36.5 percent of adults with a current ADHD diagnosis received no treatment in the past 12 months. That is not a fixed ceiling on demand — it is more than five million people with a confirmed diagnosis and no current care.

The treatment gap has several causes. First, a genuine shortage of ADHD-specialized therapists, particularly outside major metros and for BIPOC communities where diagnostic and treatment disparities have been documented for decades. Second, a widespread assumption — reinforced by the telehealth platforms' medication-first model — that stimulant prescriptions are the entirety of ADHD treatment. They are not.

The evidence base for multimodal treatment is consistent: medication addresses the neurological substrate; behavioral and psychological treatment addresses the executive function deficits, emotional dysregulation, shame history, and relationship patterns that accumulate over a lifetime of unrecognized ADHD. A client who manages their ADHD only with medication is not receiving optimal care, and increasingly, newly-diagnosed adults are learning that.

What medication addresses	What therapy addresses
Dopamine/norepinephrine dysregulation	Executive function skills and habits
Core attention and impulse control	Emotional dysregulation and rejection sensitivity
Symptom severity during medication window	Shame, identity, and late-diagnosis grief
Acute hyperactivity	Relationship and communication patterns shaped by untreated ADHD

Private practice therapists who can clearly articulate this distinction — on their website, in their intake process, and in their professional presence — are positioned for a market that is structurally undersupplied and increasingly informed about what therapy for ADHD actually offers.

ADHD therapy is not traditional open-ended exploratory talk therapy, and framing it that way on your website will cost you clients. Adults with ADHD benefit most from structured, active, skills-focused sessions — and they need to know you understand that before they reach out.

The strongest evidence base for adult ADHD is Cognitive Behavioral Therapy adapted specifically for ADHD, often called the Safren protocol after the Boston University researchers who developed it. The treatment focuses directly on executive function skills (task initiation, time management, organization), emotional regulation, adaptive thinking patterns, and procrastination — the symptoms that medication reliably does not resolve.

Other effective approaches include:

• Dialectical Behavior Therapy (DBT) for emotional dysregulation, impulse control, and interpersonal effectiveness — particularly relevant for adults whose ADHD presents with significant emotional reactivity.
• Acceptance and Commitment Therapy (ACT) for the shame, identity disruption, and avoidance patterns common in late-diagnosed adults who spent decades believing they were lazy, broken, or not trying hard enough.
• Mindfulness-Based Cognitive Therapy for attention dysregulation and the rumination cycles that accompany untreated ADHD in many adults.

The co-occurring condition profile of ADHD clients also matters for how you present your specialty. Anxiety and depression co-occur with ADHD at high rates. Adults presenting for ADHD therapy frequently have an intertwined anxiety or mood presentation that shaped their experience for years before anyone identified ADHD underneath it. If you treat these as a constellation rather than separate, sequential diagnoses, say so explicitly on your website — it is directly relevant to client self-selection and to whether AI search tools surface your practice for these queries.

ADHD is one of the clearest examples of why specialization beats generalism in search. A therapist whose website describes a broad practice in "anxiety, depression, trauma, and life transitions" competes for all of those searches and ranks well for none. A therapist whose website is explicitly organized around ADHD — with a dedicated service page, language drawn from client experience, and structured content that answers common questions — captures searches that no generalist page can.

The specific search patterns worth targeting include: ADHD therapist [city], adult ADHD therapy [city], late diagnosed ADHD therapist, ADHD therapy for women [city], and ADHD executive function therapy [city]. The "late diagnosed" phrase is particularly high-intent: adults who were diagnosed in adulthood and are processing a decades-long reframe are actively seeking therapists who understand that specific experience. If that is your client, use that language.

Psychology Today does surface ADHD-specific profile pages, but referral volume through directory listings has been declining as clients increasingly use AI search for initial discovery. Clients researching ADHD therapists on ChatGPT, Perplexity, or Gemini are routed to practices whose websites contain structured, citable information about ADHD treatment — not to directory profiles. For more on why the current therapist demand picture makes specialty visibility so consequential, the data tells the full story.

Our research into how AI engines find and cite therapists found that the practice website is the primary citation source in roughly 90 percent of AI-generated answers about local providers. A dedicated ADHD service page — structured with clear specialization, treatment approach, client population language, and credentials — is your highest-leverage move for this referral channel. The full evidence base is in our analysis of AI citation patterns for therapists.

There is a small irony worth naming: ADHD clients often do their therapist research at unusual hours, across multiple browser tabs, while doing three other things. They are quick to move on if the answer to their core question isn't immediately visible. Your website's first impression matters more with this population than with almost any other presenting concern.

What an ADHD client is looking for immediately on your site:

• Do you specialize in ADHD, or is it one item on a long list?
• Do you work with adults specifically?
• Do you use language that reflects understanding of late diagnosis, masking, and the shame that accumulates over decades of unrecognized symptoms?
• Do you offer telehealth for flexibility when executive function makes getting to an office feel impossible?
• What does a session with you actually look like?

A service page that answers these questions in the first two paragraphs, uses the language your prospective clients use to describe their own experience, and includes a clear path to contact performs dramatically better than a page that lists ADHD somewhere in a generalist specialties section.

It also performs better in AI search, where the specificity and structure of the answer is what determines whether your practice gets cited at all. A visitor agent that can handle an inquiry at 11pm when an ADHD client finally got around to their research session is the functional equivalent of a great front desk — without requiring you to be available at 11pm. Platforms like WebsiteTherapy are built around exactly this combination: specialty-optimized service pages, an AI visitor agent that engages after-hours inquiries, and the AI visibility tools that make the citation signals work in your favor.

October marks the beginning of ADHD Awareness Month. More than 15 million American adults have a confirmed diagnosis and many are actively looking for the kind of therapy that addresses what medication alone can't. The market exists. The question is whether those clients can find you.